EpiVax
EpiVax leads the industry in immunogenicity assessment and sequence optimization for biologic therapeutics and vaccines. Utilizing proprietary methods for T cell epitope identification and characterization, they employ a wide range of validated in silico and in vitro techniques to provide accurate insights into candidate immunogenicity, ensuring product safety and effectiveness. With over 26 years of experience, they serve top pharmaceutical companies and collaborate with industry, agency, and academic partners to advance immunogenicity risk assessment and vaccine design.
Industries
Nr. of Employees
small (1-50)
EpiVax
Patents
Products
Web-based immunogenicity screening and protein reengineering platform
A secure, integrated toolkit providing T cell epitope mapping, epitope hotspot detection, homology/tolerogenicity analysis, and sequence optimization tools for in silico deimmunization and benchmarking.
Automated neoantigen identification and personalized vaccine design pipeline
An end-to-end pipeline that uses a patient tumor genome as input to identify candidate neoantigens and assemble personalized cancer vaccine designs.
In silico impurity 'what-if' analysis tool
Tool that generates possible synthetic peptide impurities derived from an API (deletions, insertions, duplications, side-chain modifications) and ranks them by predicted immunogenic potential to inform impurity risk management.
Tolerance-inducing peptide sequences derived from human immunoglobulin
Short linear peptides derived from human IgG sequences that are characterized to activate regulatory T cells and modulate immune responses, proposed for applications in autoimmune disease, allergy, and tolerance induction to biologics.
Web-based immunogenicity screening and protein reengineering platform
A secure, integrated toolkit providing T cell epitope mapping, epitope hotspot detection, homology/tolerogenicity analysis, and sequence optimization tools for in silico deimmunization and benchmarking.
Automated neoantigen identification and personalized vaccine design pipeline
An end-to-end pipeline that uses a patient tumor genome as input to identify candidate neoantigens and assemble personalized cancer vaccine designs.
In silico impurity 'what-if' analysis tool
Tool that generates possible synthetic peptide impurities derived from an API (deletions, insertions, duplications, side-chain modifications) and ranks them by predicted immunogenic potential to inform impurity risk management.
Tolerance-inducing peptide sequences derived from human immunoglobulin
Short linear peptides derived from human IgG sequences that are characterized to activate regulatory T cells and modulate immune responses, proposed for applications in autoimmune disease, allergy, and tolerance induction to biologics.
Services
Multi-level computational services ranging from self-serve web access to full-service analyses and written reports for candidate screening, quantification, comprehensive analysis, and regulatory-grade evaluation.
Cell-based and cell-free assays including HLA binding, naïve CD4+ T cell activation, and innate immune assays to validate in silico predictions and provide experimental immunogenicity data.
One-on-one advisory service providing strategic guidance on candidate ranking, deimmunization prioritization, experimental planning, and preparation of immunogenicity sections for regulatory submissions.
Rapid in silico assessment of host cell protein sequences for potential to generate anti-HCP antibodies and identify HCPs that may pose immunogenicity risk.
Multi-level computational services ranging from self-serve web access to full-service analyses and written reports for candidate screening, quantification, comprehensive analysis, and regulatory-grade evaluation.
Cell-based and cell-free assays including HLA binding, naïve CD4+ T cell activation, and innate immune assays to validate in silico predictions and provide experimental immunogenicity data.
One-on-one advisory service providing strategic guidance on candidate ranking, deimmunization prioritization, experimental planning, and preparation of immunogenicity sections for regulatory submissions.
Rapid in silico assessment of host cell protein sequences for potential to generate anti-HCP antibodies and identify HCPs that may pose immunogenicity risk.
Expertise Areas
- Immunogenicity risk assessment
- Computational vaccinology
- Neoantigen-based personalized vaccine design
- Sequence deimmunization and humanization
Key Technologies
- Immunoinformatics
- T cell epitope prediction
- HLA binding prediction
- TCR-facing residue homology analysis
News & Updates
An annual event showcasing updates on immunogenicity assessment, tolerance therapies, and biologics development, with industry and academic speakers.
A forum for sharing ideas and research in immunogenicity, held annually at The Westin Hotel, Meguro, Tokyo.
EpiVax announces the appointment of Dr. Vibha Jawa as Chief Scientific Officer to lead scientific strategy.
EpiVax and CUBRC awarded a $1.1M contract by the FDA to validate the What-if Machine (WhIM), an in silico tool for peptide drug impurities.
Over 12 million sequences analyzed
EpiVax has analyzed over 12 million sequences in their immunogenicity assessments.
Served top pharmaceutical companies
EpiVax has served 17 of the top 20 pharmaceutical companies.
An annual event showcasing updates on immunogenicity assessment, tolerance therapies, and biologics development, with industry and academic speakers.
A forum for sharing ideas and research in immunogenicity, held annually at The Westin Hotel, Meguro, Tokyo.
EpiVax announces the appointment of Dr. Vibha Jawa as Chief Scientific Officer to lead scientific strategy.
EpiVax and CUBRC awarded a $1.1M contract by the FDA to validate the What-if Machine (WhIM), an in silico tool for peptide drug impurities.
Over 12 million sequences analyzed
EpiVax has analyzed over 12 million sequences in their immunogenicity assessments.
Served top pharmaceutical companies
EpiVax has served 17 of the top 20 pharmaceutical companies.